Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextroamphetamine Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

NCT01986777
View directory record Official record
Conditions
Cognitive Impairments, RRSO
Interventions
lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 17, 2026, 3:27 PM EDT
Terminated Phase 4 Interventional Results available

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

NCT02170298
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Decision Making Study in Young and Middle-Aged Adults: Part II

NCT03512171
View directory record Official record
Conditions
Healthy Adults
Interventions
Dextroamphetamine, Placebo, [18F]Fallypride, [18F]-FE-PE2I
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University
Other
Eligibility
20 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 2 Interventional

Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo

NCT00218348
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Dextro-Amphetamine Sulfate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
25 Years to 50 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

NCT00985725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Matching placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Imperial, California • Los Alamitos, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women

NCT01977625
View directory record Official record
Conditions
Menopause, Brain Activity, Cognition
Interventions
Lisdexamfetamine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

Dextroamphetamine and tDCS to Improve the Fluency

NCT02514044
View directory record Official record
Conditions
Stroke
Interventions
Dexedrine, Active tDCS, Speech Therapy, Placebo, Sham tDCS
Drug · Device · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

NCT03772314
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
Modafinil, Amphetamine-Dextroamphetamine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cocaine Use Disorder and Cortical Dopamine

NCT03349606
View directory record Official record
Conditions
Cocaine Dependence
Interventions
d-amphetamine, [C-11]FLB 457
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading

NCT00733356
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Vyvanse
Drug
Lead sponsor
Kimberley Lakes
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436162
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 17, 2026, 3:27 PM EDT
Terminated Phase 4 Interventional

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686
View directory record Official record
Conditions
Major Depression
Interventions
Tranylcypromine, Dextroamphetamine, Triiodothyronine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718483
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Corona, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 2 Interventional Results available

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01435759
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
60
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 3 Interventional Results available

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

NCT00764868
View directory record Official record
Conditions
ADHD
Interventions
Lisdexamfetamine Dimesylate (LDX)
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 17, 2026, 3:27 PM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

NCT07314333
View directory record Official record
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Attention & Memory Impairments in Menopausal Women

NCT01324024
View directory record Official record
Conditions
Symptomatic Menopause, Cognitive Impairments
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 4 Interventional Results available

Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation

NCT01924429
View directory record Official record
Conditions
ADHD
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Jeffrey Newcorn
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Differential Responses to Drugs and Sweet Tastes

NCT03810703
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Placebo oral capsule, d-amphetamine 10 mg oral capsule, d-amphetamine 20 mg oral capsule
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 19 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

NCT02478788
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
mixed amphetamine salts-extended release (MAS-XR), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Phase 2 Interventional

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

NCT02884544
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
HLD100
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 17, 2026, 3:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 17, 2026, 3:27 PM EDT